Eur Rev Med Pharmacol Sci 2015; 19 (22): 4443-4454

Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy

R. Di Francia, L. De Lucia, M. Di Paolo, S. Di Martino, L. Del Pup, A. De Monaco, A. Lleshi, M. Berretta

Hematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione “G. Pascale” IRCCS, Naples, Italy. mberretta@cro.it


OBJECTIVE: Both Fluoropyrimidine and Oxaliplatin (FluOx) are the most common anticancer drugs used to treat colorectal, ovarian, and gastrointestinal cancers.
Nevertheless, the efficacy of FluOx-based therapy is often compromised by the severe risk of neurotoxicity, cardiotoxicity, and gastrointestinal toxicity. Stratification of patients for their individual response to drugs is a promising approach for cancer treatment and cost-effectiveness. Here we evaluate the most recent findings on the most appropriate gene variants related to the toxicity in patients receiving FluOx chemotherapy.

MATERIALS AND METHODS: A systematic literature search of the MEDLINE, EMBASE, and Cochrane databases was conducted to identify all clinical studies of any association between DPYD and 5-FU correlated to allelic status of 6 validated polymorphisms in five genes Dihydropyrimidine Dehydrogenase (DPYD), Thymidylate Synthase (TYMS), Glutathione S-Transferase (GSTP1), and DNA-repair genes (ERCC2 and XRCC1).

RESULTS: The stratification of the patients into three genotype profiles group, who are most likely responders to FluOx treatments, provide informations about toxicity and/or resistance before starting therapy. Also, early evaluation cost of panel testing proposed is averaged about €100,00 per sample. The evaluation costs of genotyping before starting treatment could be a good cost-effectiveness strategy.

CONCLUSIONS: Based on the individual genomic profile, the oncologists will have new possibilities, based on the individual genetic profile, to make treatment decisions for their patients and to redefine scheduling and dosage of FluOx-based therapy.

Free PDF Download

To cite this article

R. Di Francia, L. De Lucia, M. Di Paolo, S. Di Martino, L. Del Pup, A. De Monaco, A. Lleshi, M. Berretta
Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy

Eur Rev Med Pharmacol Sci
Year: 2015
Vol. 19 - N. 22
Pages: 4443-4454